Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

Article Medicine, Research & Experimental

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

Xinghua Pang et al.

Summary: Clinical studies have confirmed that the combination therapy of antibodies targeting CTLA-4 and PD-1 significantly enhances clinical benefit compared to the use of PD-1 antibody alone. However, limited application of this combination is due to toxicities. Cadonilimab, a tetravalent bispecific antibody, demonstrates similar biological activity as the combination therapy and exhibits higher binding avidity in high-density PD-1 and CTLA-4 environments. Its Fc-null design reduces toxic side effects. These features make cadonilimab a potential candidate for improving both safety and anti-tumor efficacy.

MABS (2023)

Add to Collection

Review Dermatology

Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review

Li Zhang et al.

Summary: Sintilimab, a human anti-PD-1 monoclonal antibody, was approved for treating gastric malignancy. We present a case of a 70-year-old female patient who developed severe toxic epidermal necrolysis (TEN) 10 days after starting Sintilimab treatment. The patient did not respond to systemic corticosteroids and intravenous immunoglobulin, but showed improvement after receiving adalimumab, a monoclonal antibody that targets tumor necrosis factor-alpha. This is the first reported case of successful treatment of TEN induced by an immune checkpoint inhibitor with adalimumab.

CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma

Samuel Chuah et al.

Summary: This study identifies immune cell subsets associated with response and irAEs in HCC patients receiving anti-PD-1 therapy and proposes a new combination immunotherapy for enhanced response without exacerbating adverse events.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Cadonilimab: First Approval

Susan J. Keam

Summary: Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, has been approved for the treatment of relapsed or metastatic cervical cancer in China. It is also being developed for other solid tumors such as lung cancer and gastric cancer. This article provides an overview of the milestones in the development of Cadonilimab for the treatment of patients with relapsed or metastatic cervical cancer.

DRUGS (2022)

Add to Collection

Meeting Abstract Oncology

Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.

Li Bai et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database

Jianhong Zhu et al.

Summary: A systematic analysis of clinical trials and pharmacovigilance data revealed a significant association between immune checkpoint inhibitors and Stevens-Johnson syndrome/toxic epidermal necrolysis, with most patients discontinuing ICIs within 25.5 days of onset.

ECLINICALMEDICINE (2021)

Add to Collection

Review Dermatology